Literature DB >> 30206496

Reirradiation for locoregionally recurrent non-small cell lung cancer.

Melissa A L Vyfhuis1, Stephanie Rice1, Jill Remick1, Sina Mossahebi1, Shahed Badiyan1, Pranshu Mohindra1, Charles B Simone1.   

Abstract

Locoregional failure in non-small cell lung cancer (NSCLC) remains high, and the management for recurrent disease in the setting of prior radiotherapy is difficult. Retreatment options such as surgery or systemic therapy are typically limited or frequently result in suboptimal outcomes. Reirradiation (reRT) of thoracic malignancies may be an optimal strategy for providing definitive local control and offering a new chance of cure. Yet, retreatment with radiation therapy can be challenging for fear of excessive toxicities and the inability to safely deliver definitive (≥60 Gy) doses of reRT. However, with recent improvements in radiation delivery techniques and image-guidance, dose-escalation with reRT is possible and outcomes are encouraging. Here, we present a review of various radiation techniques, clinical outcomes and associated toxicities in patients with locoregionally recurrent NSCLC treated primarily with reRT.

Entities:  

Keywords:  Reirradiation (reRT); intensity modulated radiation therapy (IMRT); non-small cell lung cancer (NSCLC); proton beam therapy (PBT); stereotactic body radiation therapy (SBRT)

Year:  2018        PMID: 30206496      PMCID: PMC6123190          DOI: 10.21037/jtd.2017.12.50

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  92 in total

1.  Thoracic reirradiation for symptomatic relief after prior radiotherapeutic management for lung cancer.

Authors:  E L Gressen; M Werner-Wasik; J Cohn; A Topham; W J Curran
Journal:  Am J Clin Oncol       Date:  2000-04       Impact factor: 2.339

2.  Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy.

Authors:  Takuhito Tada; Haruyuki Fukuda; Kaoru Matsui; Tomonori Hirashima; Masako Hosono; Yoshie Takada; Yuichi Inoue
Journal:  Int J Clin Oncol       Date:  2005-08       Impact factor: 3.402

3.  Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer.

Authors:  Joe Y Chang; Wencheng Zhang; Ritsuko Komaki; Noah C Choi; Shen Chan; Daniel Gomez; Michael O'Reilly; Melenda Jeter; Michael Gillin; Xiaorong Zhu; Xiaodong Zhang; Radhe Mohan; Stephen Swisher; Stephen Hahn; James D Cox
Journal:  Radiother Oncol       Date:  2017-01-28       Impact factor: 6.280

Review 4.  Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.

Authors:  Joe Y Chang; Salma K Jabbour; Dirk De Ruysscher; Steven E Schild; Charles B Simone; Ramesh Rengan; Steven Feigenberg; Atif J Khan; Noah C Choi; Jeffrey D Bradley; Xiaorong R Zhu; Antony J Lomax; Bradford S Hoppe
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-01-23       Impact factor: 7.038

Review 5.  Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer.

Authors:  Salma K Jabbour; Abigail T Berman; Charles B Simone
Journal:  Transl Lung Cancer Res       Date:  2017-04

Review 6.  The use of proton therapy in the treatment of lung cancers.

Authors:  Charles B Simone; Ramesh Rengan
Journal:  Cancer J       Date:  2014 Nov-Dec       Impact factor: 3.360

7.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

Review 8.  Proton therapy in clinical practice.

Authors:  Hui Liu; Joe Y Chang
Journal:  Chin J Cancer       Date:  2011-05

9.  Current clinical trials testing the combination of immunotherapy with radiotherapy.

Authors:  Josephine Kang; Sandra Demaria; Silvia Formenti
Journal:  J Immunother Cancer       Date:  2016-09-20       Impact factor: 13.751

10.  Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.

Authors:  Melissa A L Vyfhuis; Neha Bhooshan; Whitney M Burrows; Michelle Turner; Mohan Suntharalingam; James Donahue; Elizabeth M Nichols; Josephine Feliciano; Søren M Bentzen; Shahed Badiyan; Shamus R Carr; Joseph Friedberg; Charles B Simone; Martin J Edelman; Steven J Feigenberg; Pranshu Mohindra
Journal:  Adv Radiat Oncol       Date:  2017-07-31
View more
  9 in total

1.  Early Detection of Recurrence in Patients With Locally Advanced Non-Small-Cell Lung Cancer via Circulating Tumor Cell Analysis.

Authors:  Chimbu Chinniah; Louise Aguarin; Phillip Cheng; Cristina Decesaris; Alicia Cutillo; Abigail T Berman; Melissa Frick; Abigail Doucette; Keith A Cengel; William Levin; Stephen Hahn; Jay F Dorsey; Charles B Simone; Gary D Kao
Journal:  Clin Lung Cancer       Date:  2019-05-04       Impact factor: 4.785

Review 2.  GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer.

Authors:  Núria Rodríguez De Dios; Arturo Navarro-Martin; Cristina Cigarral; Rodolfo Chicas-Sett; Rafael García; Virginia Garcia; Jose Antonio Gonzalez; Susana Gonzalo; Mauricio Murcia-Mejía; Rogelio Robaina; Amalia Sotoca; Carmen Vallejo; German Valtueña; Felipe Couñago
Journal:  World J Clin Oncol       Date:  2022-04-24

3.  Photons or protons for reirradiation in (non-)small cell lung cancer: Results of the multicentric ROCOCO in silico study.

Authors:  Esther G C Troost; Krista C J Wink; Erik Roelofs; Charles B Simone; Sebastian Makocki; Steffen Löck; Peter van Kollenburg; David Dechambre; Andre W H Minken; Judith van der Stoep; Stephen Avery; Nicolas Jansen; Timothy Solberg; Johan Bussink; Dirk de Ruysscher
Journal:  Br J Radiol       Date:  2019-12-20       Impact factor: 3.039

4.  Prognostic factors and outcome of reirradiation for locally recurrent small cell lung cancer-a multicenter study.

Authors:  Lukas Käsmann; Stefan Janssen; Andrew M Baschnagel; Tim J Kruser; Hideyuki Harada; Meryem Aktan; Dirk Rades
Journal:  Transl Lung Cancer Res       Date:  2020-04

5.  The Special Medical Physics Consult Process for Reirradiation Patients.

Authors:  Kelly C Paradis; Charles Mayo; Dawn Owen; Daniel E Spratt; Jason Hearn; Benjamin Rosen; Rojano Kashani; Jean Moran; Daniel S Tatro; Whitney Beeler; Karen Vineberg; Dylan C Smith; Martha M Matuszak
Journal:  Adv Radiat Oncol       Date:  2019-06-08

6.  Circulating Exosomal miR-96 as a Novel Biomarker for Radioresistant Non-Small-Cell Lung Cancer.

Authors:  Qin Zheng; Huaiyin Ding; Lixue Wang; Yu Yan; Yuan Wan; Yongxiang Yi; Liang Tao; Chuandong Zhu
Journal:  J Oncol       Date:  2021-02-27       Impact factor: 4.375

7.  The Impact of Radiotherapy on the Incidence of Secondary Malignancies: A Pan-Cancer Study in the US SEER Cancer Registries.

Authors:  Wei Li; Haitao Xiao; Xuewen Xu; Yange Zhang
Journal:  Curr Oncol       Date:  2021-01-08       Impact factor: 3.677

8.  Toxicity of Proton Therapy versus Photon Therapy on Salvage Re-Irradiation for Non-Small Cell Lung Cancer.

Authors:  Kyungmi Yang; Yang-Gun Suh; Hyunju Shin; Hongryull Pyo; Sung Ho Moon; Yong Chan Ahn; Dongryul Oh; Eunah Chung; Kwanghyun Jo; Jae Myoung Noh
Journal:  Life (Basel)       Date:  2022-02-16

9.  Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer.

Authors:  Julian Taugner; Chukwuka Eze; Lukas Käsmann; Olarn Roengvoraphoj; Kathrin Gennen; Monika Karin; Oleg Petrukhnov; Amanda Tufman; Claus Belka; Farkhad Manapov
Journal:  Radiat Oncol       Date:  2020-06-09       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.